A neoepitope-based enzyme immunoassay for quantification of Cl-inhibitor in complex with Clr and Cls

Scandinavian Journal of Immunology

Volumn 46, Issue 6, 1997, Pages 553-557

  Fure, H ^a   Nielsen, E W ^a,b   Hack, C E ^c   Mollnes, T E ^a  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S INHIBITOR;

ANGIONEUROTIC EDEMA; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; ENZYME IMMUNOASSAY; EPITOPE MAPPING; HUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0031454074     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-168.x     Document Type: Article

References (13)

1. Ratnoff OD, Pensky J, Ogston D, Naff GB. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C1r subcomponent of the first component of complement by serum C1 esterase inhibitor. J Exp Med 1969;129:315-31.
2. Forbes CD, Pensky J, Ratnoff OD. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J Lab Clin Med 1970;76:809-15.
3. Wuillemin WA, Minnema M, Meijers JC et al. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 1995;85:1517-26.
4. Mollnes TE, Harboe M. Neoepitope expression during complement activation - a model for detecting antigenic changes in proteins and activation of cascades. Immunologist 1993;1:43-9.
5. Laurell AB, Martensson U, Sjoholm AG. C1 activation and dissociation in disease. Immunol Lett 1987;14:249-53.
6. Laurell AB, Martensson U, Sjoholm AG. C1 subcomponent conplexes in normal and pathological sera studied by crossed immunoelectrophoresis. Acta Pathol Microbiol Scand [C] 1976;84C:455-64.
7. Nuijens JH, Huijbregts CC, Eerenberg Belmer AJ et al. Quantification of plasma factor XIIa-C1-inhibitor and kallikrein-C1-inhibitor complexes in sepsis. Blood 1988;72:1841-8.
8. Hack CE, Hannema AJ, Eerenberg-Belmer AJ, Out TA, Aalberse RC. A C1-inhibitor-complex assay (INCA): a method to detect C1 activation in vitro and in vivo. J Immunol 1981;127:1450-3.
9. Langlois PF, Gawryl MS. Complement activation occurs through both classical and alternative pathways prior to onset and resolution of adult respiratory distress syndrome. Clin Immunol Immunopathol 1988;47:152-63.
10. Mathews KP, Herschbach JH, Chambers SL, Zuraw BL. Improved method for measuring C1r-C1s-(C1 inh)2 complexes by an enzyme-linked immunosorbent assay. J Clin Lab Anal 1995;9:196-203.
11. Mollnes TE, Garred P, Bergseth G. Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. Clin Exp Immunol 1988;73:484-8.
12. Jonsson H, Sjoholm AG, Martensson U, Laurell AB, Sturfelt G. C1 subcomponent complexes and C2 cleavage in active systemic lupus erythematosus. Complement Inflamm 1991;8:1-12.
13. Turner MW. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today 1996;17:532-40.